{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T01:15:10Z","timestamp":1760577310992},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The purpose of this study was to evaluate the biodistribution and toxicity of amphotericin B (AmB) following multiple oral administrations of a novel tropically stable lipid-based formulation (iCo-010).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>BALB\/c mice were allocated into six groups: oral iCo-010 twice daily for 5 days in the dose of 20, 10, 5 and 2.5 mg\/kg; vehicle control; and intravenous boluses of Fungizone<jats:sup>\u00ae<\/jats:sup> 2 mg\/kg once daily for 5 days. The animals were sacrificed 12 h following the last administration and blood and tissues were collected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The plasma concentrations of AmB were similar to previously reported after administration of iCo-009. Somewhat lower concentrations of AmB were detected in reticulo-endothelial system in the case of iCo-010 when compared with iCo-009. The concentration in kidney was higher with iCo-010 than with iCo-009. The creatinine levels in all oral treatment groups were in a normal range as in the case of iCo-009. Administration of Fungizone<jats:sup>\u00ae<\/jats:sup> resulted in elevated plasma creatinine levels. Histopathology analysis detected no GI, liver or kidney toxicity following multiple dose oral administration of iCo-010. Fungizone<jats:sup>\u00ae<\/jats:sup> treatment induced necrotic changes in hepatic and kidney tissues.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Given the tropical stability of iCo-010, near identical activity against visceral leishmaniasis and significant concentrations in target organs this formulation has a potential to become a treatment of choice in tropical developing countries.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1476-511x-10-135","type":"journal-article","created":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T18:17:19Z","timestamp":1312913839000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model"],"prefix":"10.1186","volume":"10","author":[{"given":"Olena","family":"Sivak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Gershkovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen K","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G","family":"Clement","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kishor M","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,8]]},"reference":[{"key":"523_CR1","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/jps.21179","volume":"97","author":"JJ Torrado","year":"2008","unstructured":"Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S: Amphotericin B formulations and drug targeting. J Pharm Sci. 2008, 97: 2405-2425. 10.1002\/jps.21179","journal-title":"J Pharm Sci"},{"key":"523_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1517\/17425240902802861","volume":"6","author":"SJ Thornton","year":"2009","unstructured":"Thornton SJ, Wasan KM: The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Expert Opin Drug Deliv. 2009, 6: 271-284. 10.1517\/17425240902802861","journal-title":"Expert Opin Drug Deliv"},{"key":"523_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/jac\/dkg383","volume":"52","author":"N Lincopan","year":"2003","unstructured":"Lincopan N, Mamizuka EM, Carmona-Ribeiro AM: In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments. J Antimicrob Chemother. 2003, 52: 412-418. 10.1093\/jac\/dkg383","journal-title":"J Antimicrob Chemother"},{"key":"523_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.etp.2006.07.002","volume":"58","author":"N Lincopan","year":"2006","unstructured":"Lincopan N, Borelli P, Fock R, Mamizuka EM, Carmona-Ribeiro AM: Toxicity of an effective amphotericin B formulation at high cationic lipid to drug molar ratio. Exp Toxicol Pathol. 2006, 58: 175-183. 10.1016\/j.etp.2006.07.002","journal-title":"Exp Toxicol Pathol"},{"key":"523_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijpharm.2009.01.003","volume":"372","author":"EK Wasan","year":"2009","unstructured":"Wasan EK, Bartlett K, Gershkovich P, Sivak O, Banno B, Wong Z, Gagnon J, Gates B, Leon CG, Wasan KM: Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm. 2009, 372: 76-84. 10.1016\/j.ijpharm.2009.01.003","journal-title":"Int J Pharm"},{"key":"523_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1086\/600105","volume":"200","author":"KM Wasan","year":"2009","unstructured":"Wasan KM, Wasan EK, Gershkovich P, Zhu X, Tidwell RR, Werbovetz KA, Clement JG, Thornton SJ: Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis. 2009, 200: 357-360. 10.1086\/600105","journal-title":"J Infect Dis"},{"key":"523_CR7","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1093\/jac\/dkq358","volume":"65","author":"P Gershkovich","year":"2010","unstructured":"Gershkovich P, Sivak O, Wasan EK, Magil AB, Owen D, Clement JG, Wasan KM: Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009). J Antimicrob Chemother. 2010, 65: 2610-2613. 10.1093\/jac\/dkq358","journal-title":"J Antimicrob Chemother"},{"key":"523_CR8","doi-asserted-by":"publisher","first-page":"e913","DOI":"10.1371\/journal.pntd.0000913","volume":"4","author":"EK Wasan","year":"2010","unstructured":"Wasan EK, Gershkovich P, Zhao J, Zhu X, Werbovetz K, Tidwell RR, Clement JG, Thornton SJ, Wasan KM: A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model. PLoS Negl Trop Dis. 2010, 4: e913- 10.1371\/journal.pntd.0000913","journal-title":"PLoS Negl Trop Dis"},{"key":"523_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/jac\/dkp140","volume":"64","author":"P Gershkovich","year":"2009","unstructured":"Gershkovich P, Wasan EK, Lin M, Sivak O, Leon CG, Clement JG, Wasan KM: Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother. 2009, 64: 101-108. 10.1093\/jac\/dkp140","journal-title":"J Antimicrob Chemother"},{"key":"523_CR10","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1111\/j.1523-1755.2004.00600.x","volume":"65","author":"SR Dunn","year":"2004","unstructured":"Dunn SR, Qi Z, Bottinger EP, Breyer MD, Sharma K: Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int. 2004, 65: 1959-1967. 10.1111\/j.1523-1755.2004.00600.x","journal-title":"Kidney Int"},{"key":"523_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1208\/s12248-011-9267-8","volume":"13","author":"L Kagan","year":"2011","unstructured":"Kagan L, Gershkovich P, Wasan KM, Mager DE: Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (fungizone(R)): pooled analysis of published data. AAPS J. 2011, 13: 255-264. 10.1208\/s12248-011-9267-8","journal-title":"AAPS J"},{"key":"523_CR12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1128\/AAC.42.2.352","volume":"42","author":"N Mbongo","year":"1998","unstructured":"Mbongo N, Loiseau PM, Billion MA, Robert-Gero M: Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother. 1998, 42: 352-357.","journal-title":"Antimicrob Agents Chemother"},{"key":"523_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jep.2008.08.007","volume":"120","author":"AO Santos","year":"2008","unstructured":"Santos AO, Ueda-Nakamura T, Dias Filho BP, Veiga Junior VF, Pinto AC, Nakamura CV: Effect of Brazilian copaiba oils on Leishmania amazonensis. J Ethnopharmacol. 2008, 120: 204-208. 10.1016\/j.jep.2008.08.007","journal-title":"J Ethnopharmacol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-511X-10-135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T15:33:45Z","timestamp":1630510425000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/1476-511X-10-135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,8]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["523"],"URL":"https:\/\/doi.org\/10.1186\/1476-511x-10-135","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,8]]},"assertion":[{"value":"18 July 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"135"}}